Businesswire·2025-12-30 15:19Core Viewpoint - The proposed sale of Dynavax Technologies Corporation to Sanofi is under investigation for its adequacy in price and process, with concerns that the offered price may undervalue the company [1]. Group 1: Proposed Transaction Details - Dynavax shareholders are set to receive $15.50 in cash for each share they own as part of the proposed sale to Sanofi [1]. - The transaction is structured as a tender offer, indicating that timing may be critical for shareholders [3]. Group 2: Legal Investigation - Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating whether the sale price and the process leading to it are adequate [1]. - Shareholders who believe the transaction undervalues Dynavax are encouraged to discuss their legal rights with KSF [2].